4.3 Article

Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer

Journal

ENDOCRINE
Volume 50, Issue 1, Pages 130-137

Publisher

HUMANA PRESS INC
DOI: 10.1007/s12020-015-0575-0

Keywords

Papillary thyroid carcinoma; Radioactive iodine; Radioiodine remnant ablation; Stimulated thyroglobulin; Personalized medicine; RAI selection

Funding

  1. Abbott Laboratories Limited Canada
  2. Da Vinci Gala Fundraiser
  3. George Knudson Oakdale Pro-Am Charity Golf Tournament
  4. Department of Medicine Research Fund, Mount Sinai Hospital
  5. Mount Sinai Hospital Foundation of Toronto
  6. Alex and Simona Shnaider Research Chair in Thyroid Oncology

Ask authors/readers for more resources

The purpose of this study was to demonstrate the utility of a personalized risk stratification and radioactive iodine (RAI) selection protocol (PRSP) using post-operative stimulated thyroglobulin (Stim-Tg) and neck ultrasound in low- and intermediate-risk papillary thyroid carcinoma (PTC) patients. Patients with PTC tumors a parts per thousand yen1 cm were prospectively followed after total thyroidectomy and selective therapeutic central compartment neck dissection. Low/intermediate risk was defined as PTC confined to the thyroid or central (level VI) lymph nodes. Stim-Tg and neck ultrasound were performed approximately 3 months after surgery and used to guide RAI selection. Patients with Stim-Tg < 1 A mu g/L did not receive RAI, while those with Stim-Tg > 5 A mu g/L routinely did. Those with Stim-Tg 1-5 A mu g/L received RAI on the basis of several clinical risk factors. Patients were followed for > 6 years with serial neck ultrasound and basal/stimulated thyroglobulin. Among the 129 patients, 84 (65 %) had undetectable Stim-Tg after initial surgery, 40 (31 %) had Stim-Tg of 1-5 A mu g/L, and 5 (4 %) had Stim-Tg > 5 A mu g/L. RAI was administered to 8 (20 %) patients with Stim-Tg 1-5 A mu g/L and 5 (100 %) with Stim-Tg > 5 A mu g/L. Using this approach, RAI therapy was avoided in 17/20 (85 %) patients with tumors > 4 cm, in 72/81 (89 %) patients older than 45 years, and in 6/9 (67 %) patients with central lymph node involvement. To date, 116 (90 %) patients in this cohort have not received RAI therapy with no evidence of residual/recurrent disease, whereas among the 13 patients who received RAI, 1 (8 %) had pathologic residual/recurrence disease. Using the proposed PRSP, RAI can be avoided in the majority of low/intermediate-risk PTC patients. Moreover, traditional risk factors considered to favor RAI treatment were not always concordant with the PRSP and may lead to overtreatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available